{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:43:18Z","timestamp":1791830598697,"version":"4.3.4"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory demyelinating disease of the central nervous system with a serious, debilitating presentation, including residual disability after relapses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the economic impacts of MOGAD and analogous conditions, including direct costs, indirect costs and cost drivers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Systematic literature search and narrative review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data sources and methods<\/jats:title><jats:p>Search strings were designed to capture any study reporting health economic impacts of MOGAD or analogous autoimmune diseases of the nervous system. The costs of diagnostic tests and short- and long-term interventions were considered, and studies from both patient and institutional (public and private) perspectives were included. Searches were conducted using medical subject headings (MeSH) in PubMed in July 2023. Retrieved publications were screened initially based on title and abstract, then based on the full text. Data were extracted manually; findings are reported descriptively. All cost data were adjusted to 2024 US Dollars using the CCEMG-EPPI-Centre Cost Converter.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Results from 40 studies of MOGAD and analogous autoimmune neurological conditions were extracted. In the only study that included patients with MOGAD (a cost investigation from Germany in which 166 patients had neuromyelitis optica spectrum disorder and 46 had MOGAD), the mean annualised cost of illness was $94,688 (direct medical costs 43%, direct non-medical costs 34%, indirect costs 23%). Across the conditions assessed, the annual total cost of illness per patient ranged widely, from $3,690 to $507,117 (among studies that reported types of cost, the range for direct costs was $1,981\u2013$148,388; for indirect costs, $0\u2013$942,707). The study that included patients with MOGAD identified the need for care, number of acute attacks, unemployment and disability as independent predictors of cost. Additional cost drivers (from all the conditions) included treatments (e.g., intravenous immunoglobulin), hospitalisation, disease severity, relapses and refractory disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our search identified only one study that specifically examined costs associated with MOGAD. Results from this and studies of analogous autoimmune conditions suggest that inflammatory demyelinating diseases of the central nervous system including MOGAD are costly for the individual patient and place considerable burden on healthcare systems. Further evidence is needed for increased insight into the economic burden of MOGAD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1506465","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T13:55:44Z","timestamp":1748613344000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A narrative review of the economic burden of myelin oligodendrocyte glycoprotein antibody-associated disease and analogous conditions"],"prefix":"10.3389","volume":"16","author":[{"given":"Leonard","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Byrnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathryn","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1007\/s00415-023-11737-8","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges","volume":"270","author":"Al-Ani","year":"2023","journal-title":"J Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/ijms22010100","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management","volume":"22","author":"Ambrosius","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/jim-2019-001126","article-title":"CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease","volume":"68","author":"Rosenthal","year":"2020","journal-title":"J Investig Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2214\/ajr.20.24061","article-title":"MOGAD: how it differs from and resembles other neuroinflammatory disorders","volume":"216","author":"Shahriari","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1212\/wnl.0000000000201465","article-title":"Differentiating multiple sclerosis from AQP4-neuromyelitis optica spectrum disorder and MOG-antibody disease with imaging","volume":"100","author":"Cortese","year":"2023","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00415-021-10749-6","article-title":"Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder","volume":"269","author":"Xie","year":"2022","journal-title":"J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/s1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref8","unstructured":"2023"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s40120-023-00474-9","article-title":"Patient pathway to diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): findings from a multinational survey of 204 patients","volume":"12","author":"Santoro","year":"2023","journal-title":"Neurol Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1260358","DOI":"10.3389\/fneur.2023.1260358","article-title":"Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide","volume":"14","author":"Hor","year":"2023","journal-title":"Front Neurol"},{"key":"ref11","unstructured":"2024"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"885218","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"key":"ref14","unstructured":"2024"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s43441-022-00485-y","article-title":"Bayesian strategies in rare diseases","volume":"57","author":"Garczarek","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13023-024-03146-5","article-title":"Rare disease clinical trials in the European Union: navigating regulatory and clinical challenges","volume":"19","author":"Mishra","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"ref17","unstructured":"2024"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref19","unstructured":"2024"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1212\/01.wnl.0000316393.54258.d1","article-title":"Economic cost of Guillain\u2013Barr\u00e9 syndrome in the United States","volume":"71","author":"Frenzen","year":"2008","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13023-019-1289-9","article-title":"Out-of-pocket expenses for myasthenia gravis patients in China: a study on patients insured by basic medical insurance in China, 2013\u20132015","volume":"15","author":"Lin","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/cnd.0000000000000157","article-title":"Hyponatremia in Guillain\u2013Barr\u00e9 syndrome","volume":"18","author":"Rumalla","year":"2017","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/14737167.2022.2000862","article-title":"Chronic inflammatory demyelinating polyneuropathy in Spain: a retrospective analysis of hospital incidence and medical costs","volume":"22","author":"Darb\u00e0","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref24","unstructured":"2024"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e1184","DOI":"10.1212\/wnl.0000000000200052","article-title":"Costs and health-related quality of life in patients with NMO spectrum disorders and MOG-antibody-associated disease: CHANCE (NMO) study","volume":"98","author":"H\u00fcmmert","year":"2022","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e964","DOI":"10.1212\/WNL.0000000000006990","article-title":"Autoimmune encephalitis: a costly condition","volume":"92","author":"Cohen","year":"2019","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"822909","DOI":"10.3389\/fpubh.2022.822909","article-title":"Socio-economic burden of myasthenia gravis: a cost-of-illness study in Bulgaria","volume":"10","author":"Ignatova","year":"2022","journal-title":"Front Public Health"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mus.24109","article-title":"Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy","volume":"50","author":"Guptill","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mus.22212","article-title":"Cost analysis of myasthenia gravis from a large U.S. insurance database","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jocn.2016.11.003","article-title":"Direct and indirect cost of myasthenia gravis: a prospective study from a tertiary care teaching hospital in India","volume":"38","author":"Sonkar","year":"2017","journal-title":"J Clin Neurosci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1472-6963-11-101","article-title":"Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barr\u00e9 syndrome","volume":"11","author":"Winters","year":"2011","journal-title":"BMC Health Serv Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","article-title":"Comparative analysis of therapeutic options used for myasthenia gravis","volume":"68","author":"Mandawat","year":"2010","journal-title":"Ann Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jocn.2006.03.020","article-title":"Pharmacoeconomics of therapy for Guillain\u2013Barr\u00e9 syndrome: plasma exchange and intravenous immunoglobulin","volume":"14","author":"Tsai","year":"2007","journal-title":"J Clin Neurosci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12916-025-03875-9","article-title":"Performance of the 2023 diagnostic criteria for MOGAD: real-world application in a Chinese multicenter cohort of pediatric and adult patients","volume":"23","author":"Cai","year":"2025","journal-title":"BMC Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13023-022-02310-z","article-title":"Health utilities and costs for neuromyelitis optica spectrum disorder","volume":"17","author":"Hughes","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"117553","DOI":"10.1016\/j.jns.2021.117553","article-title":"The costs of care from a US claims database in patients with neuromyelitis optica spectrum disorder","volume":"427","author":"Exuzides","year":"2021","journal-title":"J Neurol Sci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1212\/nxi.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40120-021-00311-x","article-title":"Evaluating the economic burden of relapses in neuromyelitis optica spectrum disorder: a real-world analysis using German claims data","volume":"11","author":"Knapp","year":"2022","journal-title":"Neurol Ther."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.msard.2019.05.013","article-title":"Neuromyelitis optica testing and treatment: availability and affordability in 60 countries","volume":"33","author":"Holroyd","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1111\/ene.14746","article-title":"The long-term outcome of MOGAD: an observational national cohort study of 61 patients","volume":"28","author":"Deschamps","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12877-016-0332-0","article-title":"A critical review of the long-term disability outcomes following hip fracture","volume":"16","author":"Dyer","year":"2016","journal-title":"BMC Geriatr"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s40273-024-01370-2","article-title":"Issues, challenges and opportunities for economic evaluations of orphan drugs in rare diseases: an umbrella review","volume":"42","author":"Grand","year":"2024","journal-title":"PharmacoEconomics"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e0000745","DOI":"10.1371\/journal.pgph.0000745","article-title":"The impact of long-term conditions on disability-free life expectancy: a systematic review","volume":"2","author":"Lourida","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1212\/01.wnl.0001051416.97564.fa","article-title":"The patient journey in myelin oligodendrocyte glycoprotein antibody disease (MOGAD): results from cross-sectional patient and physician surveys","volume":"103","author":"Levy","year":"2024","journal-title":"Neurology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"103044","DOI":"10.1016\/j.msard.2021.103044","article-title":"A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: a meta-analysis","volume":"53","author":"Bai","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e2504","DOI":"10.1212\/wnl.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e209624","DOI":"10.1212\/wnl.0000000000209624","article-title":"Early maintenance treatment initiation and relapse risk mitigation after a first event of MOGAD in adults: the MOGADOR2 study","volume":"103","author":"Deschamps","year":"2024","journal-title":"Neurology"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: results of an international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J Neurol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"20552173231187810","DOI":"10.1177\/20552173231187810","article-title":"The socioeconomic impact of disability progression in multiple sclerosis: a retrospective cohort study of the German NeuroTransData (NTD) registry","volume":"9","author":"Dillon","year":"2023","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e0206205","DOI":"10.1371\/journal.pone.0206205","article-title":"The economic burden of CIDP in the United States: a case-control study","volume":"13","author":"Divino","year":"2018","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1046\/j.1351-5101.2003.00701.x","article-title":"Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"10","author":"McCrone","year":"2003","journal-title":"Eur J Neurol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/mus.26315","article-title":"Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany","volume":"58","author":"Mengel","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00415-009-5256-6","article-title":"Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy","volume":"257","author":"Schepelmann","year":"2010","journal-title":"J Neurol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ene.12245","article-title":"Economic costs and quality of life in chronic inflammatory neuropathies in southeast England","volume":"21","author":"Mahdi-Rogers","year":"2014","journal-title":"Eur J Neurol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/cnd.0000000000000301","article-title":"Longitudinal analysis of disease burden in refractory and nonrefractory generalized myasthenia gravis in the United States","volume":"22","author":"Harris","year":"2020","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jval.2018.02.008","article-title":"Economic modeling considerations for rare diseases","volume":"21","author":"Pearson","year":"2018","journal-title":"Value Health"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/trstmh\/trab118","article-title":"Costs of Guillain\u2013Barr\u00e9 syndrome in the Brazilian Federal District: the patients\u2019 perspective","volume":"116","author":"Oliveira","year":"2022","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jocn.2020.06.023","article-title":"Fatigue, self-efficacy and psychiatric symptoms influence the quality of life in patients with myasthenia gravis in Tianjin, China","volume":"79","author":"Fan","year":"2020","journal-title":"J Clin Neurosci"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.22327","article-title":"Estimated cost of treating myasthenia gravis in an insured U.S. population","volume":"45","author":"Guptill","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"120531","DOI":"10.1016\/j.jns.2022.120531","article-title":"A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment","volume":"445","author":"Ting","year":"2023","journal-title":"J Neurol Sci"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"104071","DOI":"10.1016\/j.msard.2022.104071","article-title":"First-line immunotherapy of neuronal surface antibody-mediated autoimmune encephalitis: assessment of therapeutic effectiveness and cost-efficiency","volume":"66","author":"Cai","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e891","DOI":"10.1212\/NXI.0000000000000891","article-title":"Direct economic burden of patients with autoimmune encephalitis in western China","volume":"7","author":"Li","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/jalm\/jfaa123","article-title":"A shared diagnostic stewardship approach toward improving autoimmune encephalopathy send-out testing utilization","volume":"6","author":"Sharp","year":"2021","journal-title":"J Appl Lab Med"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"116497","DOI":"10.1016\/j.jns.2019.116497","article-title":"Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?","volume":"408","author":"Allen","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"e00923","DOI":"10.1002\/brb3.923","article-title":"Home versus hospital immunoglobulin treatment for autoimmune neuropathies: a cost minimization analysis","volume":"8","author":"Le Masson","year":"2018","journal-title":"Brain Behav"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e0242630","DOI":"10.1371\/journal.pone.0242630","article-title":"Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: a Swiss cost-minimization analysis","volume":"15","author":"Perraudin","year":"2020","journal-title":"PLoS One"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1136\/ejhpharm-2020-002430","article-title":"Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study","volume":"28","author":"Piscitelli","year":"2021","journal-title":"Eur J Hosp Pharm"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00415-018-9157-4","article-title":"Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy","volume":"266","author":"Rajabally","year":"2019","journal-title":"J Neurol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/jca.21646","article-title":"Cost-minimization analysis in the Indian subcontinent for treating Guillain Barre syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin","volume":"33","author":"Maheshwari","year":"2018","journal-title":"J Clin Apher"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"e0143837","DOI":"10.1371\/journal.pone.0143837","article-title":"Hospital admissions, transfers and costs of Guillain\u2013Barr\u00e9 syndrome","volume":"11","author":"van Leeuwen","year":"2016","journal-title":"PLoS One"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"120480","DOI":"10.1016\/j.jns.2022.120480","article-title":"Real-world utilization patterns of intravenous immunoglobulin in adults with generalized myasthenia gravis in the United States","volume":"443","author":"Qi","year":"2022","journal-title":"J Neurol Sci"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/dmcn.13159","article-title":"Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome","volume":"58","author":"Nosadini","year":"2016","journal-title":"Dev Med Child Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1506465\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T13:55:51Z","timestamp":1748613351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1506465\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":73,"alternative-id":["10.3389\/fneur.2025.1506465"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1506465","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"article-number":"1506465"}}